From the Journals

More evidence links increased BMI to higher multiple myeloma risk


 

FROM BRITISH JOURNAL OF CANCER

A high body mass index in both early and later adulthood increases the risk for developing multiple myeloma (MM), according to a prospective analysis.

“This association did not significantly differ by gender but was nonetheless slightly stronger in men,” wrote Catherine R. Marinac, PhD, of the Dana-Farber Cancer Institute, Boston, and her colleagues. “MM risk was significantly positively associated with weight change and suggestive of a positive association for change in BMI since young adulthood. In contrast, we did not observe statistically significant associations of cumulative average physical activity or walking with MM risk.”

Dr. Marinac and her associates analyzed participants from the Nurses’ Health Study (NHS), the Health Professionals Follow-Up Study (HPFS), and the Women’s Health Study (WHS) with a pooled total of 575 MM cases and more than 5 million person-years of follow-up. From all of those databases, a combined baseline total of 49,374 men and 153,260 women were included in the analyses. Participants in all three of the cohorts were predominately white.

Each participant was required to report height and weight on a baseline questionnaire and updated weights on subsequent questionnaires. Using that height and weight information, the researchers calculated BMI. Physical activity also was reported using questionnaires, beginning in 1986 in the HPFS and NHS groups and at baseline for WHS, with all groups providing updates every 2-4 years. The researchers used the physical activity information to calculate the total metabolic equivalent (MET) hours of all activity and of walking per week.

Pages

Recommended Reading

Denosumab on par with zoledronic acid for multiple myeloma bone disease
MDedge Hematology and Oncology
Export protein inhibitor shows activity against refractory myeloma
MDedge Hematology and Oncology
High efficacy, no safety signals for herpes zoster vaccine post-HSCT
MDedge Hematology and Oncology
In myeloma, third ASCT is a viable option
MDedge Hematology and Oncology
Researchers question validity of NCCN guidelines
MDedge Hematology and Oncology
Drug approved to treat newly diagnosed MM in China
MDedge Hematology and Oncology
CHMP supports approval of denosumab in MM
MDedge Hematology and Oncology
Regimen deemed ‘safe and feasible’ in MM
MDedge Hematology and Oncology
Study reveals lack of sexual aids for cancer survivors
MDedge Hematology and Oncology
Drug receives orphan designation for MM
MDedge Hematology and Oncology